Harnessing the predictive power of blood-based small RNAs
Company
Hummingbird extracts deep insights into disease through the integrated analysis of both tumor and immune system derived small RNA biomarkers from whole blood.
This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.
The privately held company is based in Heidelberg, Germany.